Digital Drugs by Cornford, Tony & Lichtner, Valentina
Digital Drugs
Tony Cornford, Valentina Lichtner
To cite this version:
Tony Cornford, Valentina Lichtner. Digital Drugs. Bill Doolin; Eleni Lamprou; Nathalie
Mitev; Laurie McLeod. 5th Working Conference on Information Systems and Organizations
(ISO), Dec 2014, Auckland, New Zealand. Springer, IFIP Advances in Information and Com-
munication Technology, AICT-446, pp.149-162, 2014, Information Systems and Global Assem-
blages. (Re)Configuring Actors, Artefacts, Organizations. <10.1007/978-3-662-45708-5 10>.
<hal-01331822>
HAL Id: hal-01331822
https://hal.inria.fr/hal-01331822
Submitted on 14 Jun 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution 4.0 International License
 Digital Drugs:  
An Anatomy of New Medicines 
Tony Cornford1 and Valentina Lichtner2 
1Department of Management, London School of Economics and Political Science, London, UK 
t.cornford@lse.ac.uk 
2Decision Making Research Group, School of Healthcare, University of Leeds, Leeds, UK 
v.lichtner@leeds.ac.uk 
Abstract. Medicines are digitalized as aspects of their regulation and use are em-
bodied in or draw from interlinked computerized systems and databases. This 
paper considers how this development changes the delivery of health care, the 
pharma industry, and regulatory and professional structures, as it reconfigures the 
material character of drugs themselves. It draws on the concept of assemblage in 
presenting a theory-based analysis that explores digital drugs’ ontological status 
including how they embody benefit and value. The paper addresses three inter-
connected domains – that of use of drugs (practice), of research (epistemology) 
and of regulation (structures).  
Keywords: pharmaceutical preparations · individualized medicine · digital 
drugs · healthcare · assemblage  
1 Introduction 
Anatomy: 1. The art of studying the different parts of any organized 
body, to discover their situation, structure, and economy; dissection. 
[…] 4. The act of dividing anything, corporeal or intellectual, for 
the purpose of examining its parts; analysis; as, the anatomy of a 
discourse. (http://en.wiktionary.org/wiki/anatomy) 
 
Medicines1 and the ways we use and regulate them are changing, transformed by digi-
talization [1]. This reconfiguration is associated with visions of scientific, therapeutic, 
                                                          
1  In this paper we use the word medicines and drugs almost as synonyms. We recognise how-
ever that they offer slight but significant shifts of emphasis. ‘Medicine’ evokes the practice of 
medicine and hence the practices of medicines, while drug evokes the manufactured product 
and its chemical character/materiality. Thus in this most basic sense the thing we address has 
an inherent multiplicity. The US National Library of Medicine thesaurus (MeSH – Medical 
Subject Heading) avoids this tension in its own way using the term Pharmaceutical Prepara-
tions – “Drugs intended for human or veterinary use, presented in their finished dosage form” 
(NLM - Medical Subject Headings - 2014 - Unique ID D004364 - 
managerial and financial breakthroughs from ‘better’ medicines and in particular ‘bet-
ter’ digitally mediated medicine use practices. Expectations include: help in meeting 
the needs of aging populations with multiple chronic diseases, the targeting of medi-
cines to individuals (personalization) to significantly increase efficacy and reduce over-
all cost, and computerized clinical decision support that can reduce the burden of harm 
caused by adverse drug events (ADEs). The pharma industry too is reconfiguring as it 
faces increasing competition from ‘generics’, reductions in the pipeline of new medi-
cines entering the market and the ‘patent cliff’ off which large pharma companies fear 
to fall [2, 3]. Such pressures spur changes in how current drugs are marketed, distrib-
uted and paid for [4]. Pharmaceutical business models are realigned to build new rela-
tions between patients, health care institutions and the pharma industry, with drug prod-
ucts enmeshed in or recast as a set of services, and with payment (pricing/reimburse-
ment) shifting from the ‘product’ to outcomes.  
 The digitalization of medicines is reflected in a number of overlapping areas of con-
temporary research and development including electronic prescribing, stratified medi-
cine, personalized medicine, smart drug platforms, medical profiling, pharmacovigi-
lance, value based pricing and pharmacogenomics (Table 1). The specifics of the 
‘breakthrough’ vision vary, as do the digital mechanisms and resources that are imag-
ined or deployed, but taken overall these initiatives seem to offer new possibilities for 
therapeutic improvement and innovation through digitally mediated ways of using 
drugs. We believe they also foreshadow multiple possible changes in broader medical 
practices, institutional structures, value chains and business models.  
This paper presents a theory-based view of what we term digital drugs, including 
how they embody benefit or value. The work is part of the scoping of a RCUK funded 
project addressing how, why and with what consequence medicines are digitalized. In 
contrast to the established view of medicines as artefacts located in a stage-based model 
of linear progression from drug development, through innovation and testing to ap-
proval and clinical use [5] this work sees drugs as constituted ‘in-use’[6], as performed, 
and with their agency located and expressed within and as connections among soci-
otechnical and economic contexts. In the wider project we ask three primary questions: 
1) what is a digital drug - exploring the conceptual and analytical shift from physi-
cal/chemical artefacts towards some digital sociomateriality; 2) how use-practices, 
markets and business models evolve for semi-configured and servitized kinds of med-
icines; 3) consequences for/changes in the ‘wider whole’ and the relations between the 
parts/players (pharma and health industries, payers, research, regulatory practices, pa-
tient-doctor relations, etc.). Cutting across these areas are multiple questions of value: 
therapeutic value, clinical value, health enhancement, value as management of risk or 
reduction of harm, market value, value in exchange, value in use, value for money, and 
ethical values.  
 
                                                          
http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?mode=&term=Pharmaceutical+Preparation
s&field=entry – Accessed 15 Sept 2014). 
 Table 1. A sample of contemporary digital hybrids in medicines use 
Concept  Definitions Digital mechanisms 
Electronic  
prescribing 
(EP) 
“The utilisation of electronic systems to facilitate and 
enhance the communication of a prescription or 
medicine order, aiding the choice, administration and 
supply of a medicine through knowledge and decision 
support and providing a robust audit trail for the entire 
medicines use process.” (Connecting for Health, quoted 
in [7]) 
On DSS, see also: [8]. For an example of the 
application of DSS and EP in personalized medicine 
see: [9]   
Decision support; 
error reduction; 
contributing to 
electronic patient 
record and Big Data 
repositories.  
Stratified  
medicine (SM)
 
“Refers to the targeting of treatments (including 
pharmacological and non-pharmacological 
interventions) according to the biological or risk 
characteristics shared by subgroups of patients.” [10]  
See also:  [11] 
Often combined with, or used as synonym for 
Personalized medicine (PM)  
“Targeting therapy 
and making the best 
decisions for groups 
of similar patients”; 
finding those who 
benefit most (or face 
greater risk), finding 
those who respond to 
this treatment.  
Personalized 
medicine (PM)
“An emerging practice of medicine that uses an 
individual’s genetic profile to guide decisions made in 
regard to the prevention, diagnosis, and treatment of 
disease. Knowledge of a patient’s genetic profile can 
help doctors select the proper medication or therapy and 
administer it using the proper dose or regime” (National 
Human Genome Research Institute, cited in [8]).  
See also: [12] 
Targeting therapy and 
making the best 
decisions for a 
specific patient, on 
the basis of how the 
body will respond to 
treatment; selecting 
the right/best therapy 
on the basis of the 
patient’s ‘omics’ and 
expected response to 
active ingredient(s). 
 
Smart Drug 
Platforms 
(SDP) 
“The same pharmaceuticals you take today, with one 
small change: each pill [contains] a tiny sensor that can 
communicate, via a digital health feedback system, vital 
information about medication-taking behaviors and 
body’s response” (paraphrased from [13]). Also seen in 
wearable devices often linked to mobile phone e.g.  
Apple HealthKit.  
 
Smart pills, smart 
patches (e.g. [14]). 
Devices and platforms 
for data acquisition 
and analysis.  Tight 
feedback on 
medicines as released 
in the body.    
Medical 
profiling (MP)
 
The process of determining a patient’s ‘omics’ (a 
person’s characteristics in terms of molecular 
components and biological pathways, such as genes, 
transcriptomic, proteomic, metabolomic, and 
autoantibody) for purposes of PM or SM [15]. See also: 
[16] 
Informing SM 
categorizations and 
PM therapeutic 
decisions. 
Value based 
pricing (VBP) 
Payment to drug suppliers on the basis of the 
therapeutic benefit achieved. [35, 36] 
Linking outcome data 
at patient level to 
payment; rebalance 
risk/reward 
Pharmaco-
vigilance (PV)
The assessment of the public health importance of 
potential new signals found in medicines-use data (e.g. 
adverse drug reactions) and the confirmation and 
quantification of risks identified and risk minimization  
measures (paraphrased from [17]). 
For an example of use of digital sources (e.g. social 
media) for this purpose, see [18] 
Adverse event 
reporting systems, 
population scale 
outcomes data via 
EHR; prospective 
analysis.  
Pharmaco-
genetics (PG) 
“Examines inherited or acquired variations in genes that 
dictate drug response, disposition, or toxicity and 
explores how these variations can be used to optimize 
medication therapy.” [19]  
Similar to PM and MP, but specific to genetic profile 
and pharmaceutical therapy. 
Genomics and 
genomic profiling; 
epidemiological 
resources. 
Anti-counter-
feiting (AC) 
Falsified medicines are fake medicines that pass 
themselves off as real, authorized medicines. Falsified 
medicines may: contain ingredients of low quality or in 
the wrong doses; be deliberately and fraudulently 
mislabeled with respect to their identity or source; have 
fake packaging, the wrong ingredients, or low levels of 
the active ingredients (paraphrased from European 
Medicines Agency web site). See also: [20] 
Supply chain 
integration (bar codes, 
security codes; tamper 
proof packaging); 
consumer services 
(website seals/logos) 
and digital services.  
2 Origins and Character of Digital Drugs 
Medicines have always been hybrids (actor networks) - in part biochemical actor (active 
molecule(s)), in part material delivery system (pill, infusion, suppository, box, leaflet, 
cold chain), in part informational resources (representations and scripts to validate ther-
apeutics and designate safe and appropriate use). And all bound up with complex and 
diverse social, scientific and economic interests and practices. However, the examples 
in Table 1 suggest that contemporary medicines in use become more materially, infor-
mationally and algorithmically complex, e.g. more digitally potent. We identify these 
as digital drugs2 – that is: 
                                                          
2  There is a possibility that something like a clinical medicine might emerge and be adminis-
tered in a form that is essentially a pure digital phenomenon, e.g. an abstract ‘program’ of 
biochemical action to be compiled, ‘downloaded’ and ‘run’ in the body. More simply, a ther-
apy such as a gym routine might be seen this way. For example the UK NHS ‘Couch to 5K’ 
is a therapy embodied in podcast downloads for achieving basic fitness through running [21]. 
A Google search of ‘digital drugs’ will also give information on possible audio-based psycho-
tropic recreational drugs – so called ‘digital highs’. In the sense that music can change your 
mood, perhaps even suppress pain, this is plausible. However, the general professional opin-
ion is that the technology of ‘binaural beats’ is an interesting sensory phenomenon but psy-
chotropically ineffective and that those who do get high are experiencing at best a placebo 
effect [22]. 
drugs that are both dependent on and substantially constituted by 
multiple digital representations and connections, and whose use and 
effectiveness is strongly mediated through digital means.  
The lens we use to study digital drugs is assemblage [23] – drugs as performed bun-
dles of artefacts, interests and practices that connect and interact with wider wholes, 
including clinical work (use), research practices that validate utility/value and miti-
gate/metricate risk (clinical trials, systematic reviews, pharmacovigilance) and regula-
tory frameworks to guide practice (regulations, protocols and guidelines).  
In using the concept of assemblage we follow the broadly Deleuzian approach [23, 
24]. Assemblage signifies digital drugs as events and conjunctions in time and sources 
of qualitative difference (something happening, some things entangled, something no-
ticed, something different, a process or processes at work, an enactment). In the Deleu-
zian vocabulary an assemblage is rhizomic, a question of emergence (emergent prop-
erties, generativity) in open systems – “the always-emergent conditions of the present” 
[23]. An assemblage is not then a ‘thing’ (as in a network), with specific life-span or 
essence. Rather, assemblage is understood in a metaphysics in which “the concept of 
multiplicity replaces that of substance, event replaces essence and virtuality replaces 
possibility” [25]. This implies actions and performance of complex and multiple cau-
sality/functional interdependencies (e.g. as a medicine is found in a body or bodies, 
modeled in a genomic profile, supplied, or prescribed), and is not tied to a fixed format 
or a single unambiguous event or outcome. This is in contrast to the term hybrid used 
here to refer to the (digital) drug as artefact and actor, including its mix of material/dig-
ital resources and its evolved sociomaterial agency. We might say that assemblage is a 
concept applied to the ‘instantiation’ of the drug hybrid in use – the ‘here and now’ in 
a context (including in virtual contexts and in simulations).  
We approach digital drugs by opposing the concept to its non-digital or pre-digital 
i.e. analogue version. The generations of medicines within our established regulatory 
structures, including the post-Thalidomide medicines, are essentially analogue drugs –
seen as organic artefacts operating in an organic world of the body. Norbert Wiener, 
commenting on the probabilistic world of quantum mechanics, notes “the recognition 
of a fundamental element of chance in the texture of the universe” [26, p. 11]. In this 
sense anything analogue/organic is incomplete and uncertain (“...this random element, 
this organic incompleteness” [26, p. 11]). This ‘incompleteness’ certainly applies to 
medicines and their use. We are used to (or resigned to) the ‘quantum’ effect in medi-
cines even as we strive for a stronger and stronger evidence base and thus certainty. 
Indeed the quantum is rather large given that most drugs prescribed to people do not 
work as desired most of the time3. Contemporary moves to digitize medicines may be 
                                                          
3  The average NNT (Number Needed to Treat) for a licensed drug used in secondary care is 
well over 5, and for a prophylactic drug (e.g. aspirin for prevention of stroke) it may be well 
over 1000; that is over 1000 persons need to receive the drug, including paying for it and 
suffering possible side effects, for one to obtain a therapeutic benefit [27]. As a point of con-
trast everyday paracetamol (acetaminophen) which a dentist may give you after an extraction 
has an NNT of around 4.5 for post-operative pain [28]. 
seen as an attempt at closing down ‘this organic incompleteness’ within a digital cer-
tainty – e.g. through stratified medicine, genomics etc. as well as anti-counterfeiting 
systems or pharmacovigilance. It is tempting to imagine, as some proponents of these 
approaches do, that the shift to digital will drive down the quantum effect as it opens 
access to mechanisms that can validate actions and reduce error terms by orders of 
magnitude. This is not our position. Through the concept of assemblage, we argue, the 
quantum of the digital is made apparent, seen for example, in the simulated or more 
generally in the multiplicities that digital ontology accommodates.   
 Yoo’s definition of digitalization recognizes this transition from analog to digital as 
fundamental: “the encoding of analog information into a digital format and the possible 
subsequent reconfigurations of the socio-technical context of production and consump-
tion of [the associated] products and services” [29, p. 137]. He proposes that such dig-
italization occurs in various ways: at the level of a physical object (e.g. a digital infusion 
pump in place of an analog gravity infusion roller clamp; a 3D tamper proof bar code 
on a package), at the level of digital/digitally mediated routines (a digital algorithm for 
prescribing; a smart phone app to raise adherence to therapy), or as new representations 
(a genomic account of personalized efficacy; a digital information resource on drug-
drug interactions driven by massive electronic health records databases).  
Any division between a digital drug (and digital quantum) and an analogue drug (and 
organic quantum) is not of course clear cut. Transitions occur over years as existing 
resources are reconfigured in digital forms and new resources added or retro-fitted. Our 
argument is, however, that as more of the active work we expect medicines to do (their 
agency) is (co)located in the digital, as digital resources and mechanisms are added and 
combined, and as this agency (re-)aligns to specific interests and goals, be they thera-
peutic, social or economic, then the nature of what a drug is, and how a medicine of 
medicines is practiced, ‘tips’ and something distinct and new emerges – a different kind 
of drug, a different set of practices, different assemblages. This in turn implies, we 
argue, new social, organizational and market structures.  
Thus, as Yoo’s definition of digitalization suggests and as assemblage requires, our 
interest is not focused ultimately on the digitizing of the information/object or the new 
digital routines or new representations, significant though these are – and of course we 
do need to consider the specific characteristics of digital products and services (as prod-
ucts/artefacts and as representations/services) and the ‘bit string’ economics that they 
obey [30]. But it is the ‘subsequent reconfigurations’ that are foreshadowed as seen in 
events and actions that we explore.  
3 Three Domains: (In-)Use, Research, Governance 
We approach digital drugs as assemblage from the perspective of three traditional do-
mains in which they are by convention ‘assembled’ and within which issues of their 
value are addressed. These are the domain of clinical and therapeutic use, the domain 
of reflexive enquiry and research (gathering of ‘evidence’, knowing), and the domain 
of regulation and governance. These three domains are well established, each with its 
own practices and an established role/narrative as how we benefit (or not) from medi-
cines. We do not consider here the biochemical domain, important though it is. These 
domains are of course interlinked, and one of the characteristics of medicines digitiza-
tion is that these domains connect more and more e.g. events/assemblages are larger, 
stronger, richer, and more dynamic.  
3.1 In-Use 
As suggested above, digital drugs emerge in part out of efforts to computerize existing 
medicines use practices (prescribing, supply, administration, adherence, etc.) and in this 
way ‘digitalize the object’ with consequential ontological changes. Since the turn of the 
millennium it has been a key ambition of developed country health care policies to 
computerize prescribing in both primary care and secondary care and specifically to 
exploit the benefits of clinical decision support systems (CDSS) in helping prescribers 
select the right medicine for the patient, and to do so on the basis of a (digital) medical 
record (e.g. providing clinical data including in areas such as allergies), and data on 
recommended therapeutic strategies, available medicines, cost/cost effectiveness, and 
the effects of interaction among them (e.g. [31]). Similarly in the administration of 
medicines to or by patients, technological systems and devices such as smart pill boxes 
or text alerts are deployed to encourage or enforce adherence and record actual use [32]. 
Much of this work has necessarily been piecemeal (perhaps better described as ‘tar-
geted’) as specific clinical practices and operational needs have been given computer 
‘support’ (prescribing, dispensing, supply, administration, audit, ‘academic detailing’, 
phamacovigilance, etc.). CDSS are also understood as a necessary technological infra-
structure, a necessary representation, without which a widespread application of per-
sonalized medicine cannot be contemplated [33], e.g. to enable the use in clinical prac-
tice of the 2500 genetic tests now already available [8, 34].  
The potential therapeutic value and/or service value that motivate such projects in-
clude improved safety and reduction in errors and harm, more consistency of (good) 
practice, more efficient operations with less waste, and better documented therapy. In 
this way initiatives to computerize medicines-use are by convention set against the fa-
miliar litany of contemporary existential health care problems: rising health care costs, 
unacceptable error rates and the harm they cause, demographic change, managing a 
growing burden of treatable chronic disease. Ambitions of progress in these areas are 
predicated on the existence of good informational infrastructures that represent valid 
forms of data (e.g. [35]). Many of these ambitions have not yet been fully met but the 
quality, coverage and scale of data infrastructures improves over time.  
More system-focused policy motives reflect a desire for more net value (i.e. more 
health benefit and less harm) and value for money out of budgets for medicines. In the 
English NHS about 50 million population generate a yearly drugs bill of about £12bn. 
This leads to a perceived need to exploit digital technologies both to help control this 
significant line of expenditure and to increase the effectiveness of what is spent in im-
proving health outcomes.  
Models of the use of digital drugs and their regulation are founded on ideas of digital 
systems for establishing efficacy, expressing protocols and in the realization of individ-
ual patient’s care pathways. This approach to medicines and their use is portrayed as 
offering a ‘personalized’ (or stratified) service (or services) wrapped around the medi-
cine. Perhaps most significantly, the personalization process – the process to match 
your genetics and medical history, test results and other ‘omics’4  to what is known 
about medicines and therapy - becomes a separate institutional endeavor. Thus a new 
industry of ‘diagnostics’ has emerged (with economic value) which serves through de-
vices, tests, data analysis and protocols to control and target therapy choice and therapy 
delivery – generating a trajectory of events. This is an arena of practice in which the 
balance of business interests and clinical or public health interests is today unclear. 
More generally the development of an industry and services for diagnostics can be seen 
as an example of a ‘service-dominant logic’ (servitisation) [36] as a drug becomes less 
a standard product, and is more performed by a complex set of value generating ser-
vices (value here being taken in multiple senses of the word; see above). The clinical 
utility of the therapeutic intervention (its relevance and usefulness in patient care [37]) 
“becomes a moving target” as information on its benefits and risks increases for groups 
or for individual patients [37]. As part of this, ’patients’, their bodies and their carers 
may (but it is in no way inevitable) become more active participants in therapy, with 
their involvement too digitally mediated – a possible reconfiguration of the patient and 
their role as actor and information source (e.g. in consultations) to a data source (e.g. 
through wireless monitors or smart pills).  
The health value a medicine generates, and the ability to identify this, becomes an 
open and multiple question – how to find a value-in-use (e.g. the model of a market in 
services, and in particular digital services). This moves away from traditional ideas of 
a value-in-exchange (the model of a market for products). This change in perspective 
is directly seen in contemporary policy debates as national systems and payers consider 
‘value based pricing’– e.g. paying (or not paying) for the therapeutic service (or out-
come), not for the molecule, and using a multi criteria algorithm and feedback to iden-
tify those that pass the value test and those that fail it [38, 39]. 
3.2 Research – Evidence in the Doing 
A large armory of methods and techniques are today available to support scientific en-
quiry into medicines biochemical efficacy and other consequences and side effects (e.g. 
their validation as safe and effective) including statistical measures of outcomes as in a 
controlled trial, and synthetic metrics such as Number Needed to Treat (NNT) and 
Number Needed to Harm (NNH). These methods, refined in the past 70 or so years, 
underpin the established processes through which a new medicine is developed, tested 
                                                          
4  Omics: a neologism used to describe a range of scientific fields (proteomics, genomics etc.) 
studying important biomedical aspects about a patient or patient group for subsequent use in 
personalised or stratified medicine; used also to refer to a person’s characteristics in terms of 
molecular components and biological pathways (e.g. transcriptomic, proteomic, metabo-
lomic). 
and then licensed for specific uses. It is also the basis for the primary means by which 
a healthcare professional is given guidance on what medicines to use, when and how. 
Research findings are synthesized into protocols or guidelines for practitioners based 
on clinical data with or without some element of health economics (value for money).  
In the UK for example, a national body - the National Institute for Health and Care 
Excellence (NICE) - prepares guidance on drug treatments which balances clinical and 
therapeutic benefits against cost5.  Fundamental to this is the use of randomized control 
trials (RCT) and the types of knowledge that can be derived from trials, both individu-
ally and through meta-analysis (e.g. Cochrane reviews). It is in this way that we confi-
dently (i.e. within confidence intervals, given the ‘random element and organic incom-
pleteness’ of life) assert the therapeutic value and risks of a new medicine for specific 
conditions and/or subpopulations, or recompute them for older drugs. However clinical 
trials in their traditional form are increasingly considered unsuitable to obtain the evi-
dence on benefits and risks of medicines tailored to specific individuals – for example 
a trial now has to assess both the efficacy of the treatment and the efficacy of the diag-
nostic that underpins the stratification, the co-dependent development of drugs and mo-
lecular diagnostics [40]. As Lewis et al. suggest of personalized medicine “[It] forces 
us to question contemporary biomedical views of evidence, including its generation and 
use in decision making” [40]. There is thus a new focus on a set of complementary 
approaches to metricate value generated by medicines as they are to be used and as they 
are revealed through intensive digitization in the domain of use. Individual patient data 
collected/entered by clinicians at the point of care, or provided by the patient (now a 
data source), are aggregated into ‘Big Data’ as a potential basis for a new knowledge. 
A range of new analytic tools analyze or ‘mine’ these often non-standardized data and 
sift through the ‘data turmoil’ [41].  Among these analytic resources, for example, are 
new data-driven approaches to test the relationship between biomarkers and clinical 
outcomes [42] or for standardizing function instead of components in RCTs of complex 
interventions [43]. Alternatively, “real-time surveillance of individual patient out-
comes” [37] may complement trials and improve evidence and support personalization. 
Drawing on digital resources, trials and experiments can be set up as “randomized stud-
ies embedded in routine care” through the use of electronic patient record databases 
[41]. Through such means the duration of trials and evidence gathering will shorten, 
some hope. For example, with an active distributed surveillance system in place “a full-
scale observational study to evaluate the association between angioedema and drugs 
targeting the renin–angiotensin system was designed, conducted, and completed in 11 
months” [44]. The perception of the need for such methods and the sense of urgency to 
exploit new research opportunities can be traced in part to the case of the pain killer 
and anti-inflammatory drug Vioxx. This medicine was licensed in 1999 and withdrawn 
in 2004. It took over 3 years and a number of patient deaths (disputed but probably in 
6 digits [45]) before the negative side effects were acknowledged by the makers and 
the drug withdrawn from the US market [46]. The proposition is that, with digitalized 
                                                          
5  http://www.nice.org.uk/guidance/index.jsp?action=bytreat-
ment&TREATMENTS=Drug+treatments Last accessed 15 September 2014 
patient records, and an effective and proactive pharmacovigliance system, such a case 
could be identified earlier with overall less harm [44]. 
3.3 Governance and Regulation  
Research designs reflecting digitization, as described above, imply significant modifi-
cations to regulatory regimes. Regulators have been among the most active in adapting 
to the new world of digital drugs. The FDA, the US regulator, has made many changes 
in its processes to accommodate a perceived new urgency in drug approval processes 
including a fast-track process for ‘breakthrough therapies’ [47]. There is a somewhat 
similar designation of ‘orphan drugs’ in medical areas where patient numbers are small 
and investments are unlikely to be made on the usual commercial basis. If and when 
medicines are fast tracked (a concept with a history traced back to the early period of 
HIV/AIDS), and are expected to have a weaker research provenance at the time of li-
censing, they rely more on digital resources for monitoring of “post marketing safety 
and effectiveness” [44]. In such circumstances medicines-in-use data can serve to “raise 
or lower the level of concern about the overall risk–benefit profile of particular drugs”, 
a capability that is described by the FDA as being transformational for the licensing 
process [44]. More generally they acknowledge the ability of these new resources of 
data to help fulfil the FDA’s role. In the own words of the FDA, it has “evolved its 
regulatory processes in response to – and in anticipation of – scientific developments” 
[48], noting how it has responded to personalized medicines and the associated growth 
of diagnostic products by, “collaborating in key research, defining and streamlining 
regulatory pathways and policies, and applying new knowledge in product reviews” 
[48].  Meanwhile, Australia has, arguably, the first national framework to assess per-
sonalized medicine for coverage or reimbursement decisions [49]. 
As suggested above, digitization and the availability of data generated in clinical 
care practices (in-use) and held in national registries, migrate from a pure research 
(trial) status to embody more directly various interests including of health care system 
managers and the payers, patients and patient groups, and the pharmaceutical industry 
[50, 51]. That is, research in both new and old formats, and digitalized and synthesized 
prospective data sets become engaged in the systems of governance and regulation that 
surround medicines use. Research data thus will directly feed the development of de-
tailed and comprehensive protocols of use (and non-use) for powerful and expensive 
drugs, described as frameworks for ‘appropriate medicines use’ [50]. Niezen et al. re-
port research in The Netherlands on registries (national databases of medicines use for 
a specific class of patient) as digital artifacts that are both an object to be managed, and 
an instrument to manage with. In this way clinical work (using medicines with patients 
and feeding the registry) and regulatory work (setting the protocol guidelines and reim-
bursement rules) become closely co-constitutive and co-evolving. In their analysis they 
question the desirability of a regulatory system that pursues a new ‘digital objectivity’ 
where available data embodies truth – as seen in many Big Data endorsements, and 
captured in the idea of the ‘death of the denominator’ when  n=All (see also [52]). They 
contrast such digital objectivity with the more established ‘regulatory objectivity’, the 
kind of knowledge that is based on multiple evidential resources and embodies conven-
tions and trade offs and collective expertise [53, 54].  
4 Conclusion 
In this paper we introduce the new concept of digital drugs as the intensified integration 
of digital services, data resources and algorithms into the practices of medicines. We 
anatomize it to reveal some of the main components (use, regulation, research) and 
mechanisms and relations using the lens of assemblage. The digitalization efforts that 
characterize the movement towards digital drugs are for the most part undertaken in the 
name of understanding, best practice, precision, and certainty. The individual initiatives 
and innovations described here can be seen individually as the expression of some reg-
ular and rational plan or policy to enhance the efficacy and efficiency of health care. 
Our view, our conceptual repertoire, and our chosen lens of assemblage, however, sug-
gest something else or at least a different account of motivations and mechanism. As 
proposed here, digitization (digital mediation of drugs) is pursued as a means to address 
the organic quantum of chemicals in the body. However, the complexity and multiplic-
ity of elements that converge in or constitute a digital drug and its ‘use/reuse’ suggest 
that it need not, and perhaps should not, be seen as a pursuit of a certain or specific 
outcomes. Digital drugs are manifest as diverse, distributed, cumulated and dissected 
events and incidents across and between domains. They also permit multiple outcomes 
as data resources grow, algorithms learn and reconfigure, and virtual phenomena take 
new roles. Such multiplicity and instability is a price paid for the desired outcomes, for 
example in the case of in-use experimental designs or big data driven protocols (digital 
objectivity). 
Markus and Saka introduce assemblage as a technique of collage and “something 
that generates enduring puzzles about ‘process’ and ‘relationship’” and “[offers] an 
odd, irregular and time-limited object for contemplation” [23]. Applying it in these 
terms to medicines, this paper raises issues that might be assessed against a wider un-
derstanding of digitalization.   
First, is the idea of digital drugs themselves, or more generally of movement (re-
configurations) towards a digital materiality that attaches to and ‘takes over’ classes of 
artifacts. In this it recasts them ontologically away from an artefactual existence to one 
of assemblage - found in a complex ecosystem of data, algorithm and temporally un-
stable conjunctions, actual, real, virtual or simulated. 
Second, and embedded within this perspective, is the question of the ’mechanisms’ 
of the digital as rational processes of improvement, as (digital) controllers, as sense-
making, and as generative forces. Our case, and the examples in Table 1, suggests that 
there is opportunity here for useful fundamental categorizations of this digital agency 
through artefactual and assemblage conceptualizations. 
Third and finally, is the question of knowledge processes (research designs) as em-
bedded in these phenomena. The methodological arsenal of the evidence based com-
munity (that of innovators, regulators and evidence-based practice) is changing and 
adapting. Event and transaction are at the core, able to be inspected, accumulated and 
animated in ways that were not possible in earlier eras. This reconfiguration is core to 
the phenomena of interest.  But can the IS community reconfigure its research agendas 
and methods to meet this challenge?  
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